Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2034 participants.

Also called NCT07566091

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,034 participants (planned count) (from the registry)
Sponsor
Jung-min Ahn (from the registry)
Registry
  • NCT NCT07566091
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07566091. Randomized; double masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2027-06-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
Acronym
NOVA
Intervention (Device)
Sirolimus-Ascorbic Acid Eluting Stent
Intervention (Device)
Everolimus-Eluting Stent
Lead sponsor
Jung-min Ahn (class: other)
Collaborator
The CardioVascular Research Foundation (CVRF) (class: not stated)

Record details

Record id
cardio:ct-nct07566091
Content hash
c30873fe9bcb44dcad975407a001b4c3825857ce3919c0e5839775229f047fe5